Master of Public Health
First Committee Member
David Brett-Major, MD, MPH
Second Committee Member
Keyonna King, DrPH, MA
Third Committee Member
M. Jana Broadhurst, MD, PhD, DTM&H
The OraQuick In-Home HIV Test was FDA-approved for over-the-counter use for people aged 17 years and older in 2012. The FDA reported on the sensitivity and specificity of the test, which looks at the accuracy of a test relative to a reference standard. However, the predictive values that account for prevalence still need to be thoroughly examined among tests distributed through community-based means. In this review, we looked at the predictive values for the OraQuick In-Home HIV Test for people aged 15 years and older when the test is distributed through community-based means. We calculated the predictive values for each study and key demographic groups. While most participants had positive experiences with the test, there were test collection and interpretation issues. In the studies, trained personnel provided differing levels of observation, training, and help. We organized the studies by their level of assistance from trained personnel. Overall, participants preferred having trained personnel with them during collection and interpretation. Trained personnel also interpreted fewer invalid or indeterminate results than study participants. There need to be more studies with larger study populations and real-world scenarios where study participants buy the test themselves and complete them at home without additional assistance. We would also like to see pharmacies that offer the test offer assisted tests with trained pharmacy workers.
Zinn, Mariah, "A Scoping Review of the Predictive Values and Use of the OraQuick In-Home HIV Test" (2023). Capstone Experience. 250.
Available for download on Saturday, April 27, 2024